PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are
at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce
the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or
epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also
been identified as the most problem for breast cancer patients under adjuvant chemotherapy.
In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment
among stage II/III breast patients under adjuvant EC regimen in reduction of
chemotherapy-induced toxicity and encouraging compliance with chemotherapy.